• Hangzhou Diagens reported revenue of RMB 108.7 million for the six months ended June 30, 2026, up 21% year on year.
• Loss widened to RMB 55.9 million from RMB 1.3 million a year earlier; R&D costs climbed 67.4% to RMB 64.1 million.
• Model services revenue more than doubled to RMB 94.5 million, rising 101.1% year on year and accounting for about 86.9% of total revenue.
• Medical imaging software and devices revenue fell 71.8% to RMB 11 million, due to delayed client budgets, tendering, delivery or acceptance.
• AI AutoVision received a China NMPA Class III registration certificate in May 2026; the product entered early-stage commercialization preparation and execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Diagens Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12276735), on August 07, 2026, and is solely responsible for the information contained therein.